Emergent BioSolutions Inc (EBS)
7 Dec 2016
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|58||2012||Executive Chairman of the Board|
|61||2012||President, Chief Executive Officer, Director|
|58||2012||Executive Vice President - Corporate Services Division, Chief Financial Officer and Treasurer|
|45||2011||Executive Vice President and President - BioDefense Division|
|60||2011||Lead Independent Director|
- BRIEF-Emergent Biosolutions Q3 adjusted EPS $0.58 from continuing operations
- BRIEF-Emergent biosolutions provides update on biothrax procurement contract and discussions with CDC
- BRIEF-Emergent awarded BARDA contract for advanced development of NuThrax
- BRIEF-Emergent Biosolutions gets FDA approval for large-scale manufacturing of Biothrax in building 55
- BRIEF-Emergent announces conversion rate adjustment to 2.875% convertible senior notes